BIOXYTRAN, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
BIOXYTRAN, INC. (BIXT) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$332.53 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- BIOXYTRAN, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$46.87K.
- BIOXYTRAN, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$806.00.
- BIOXYTRAN, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$16.06K.
- BIOXYTRAN, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$141.60K, a 121.22% decline year-over-year.
- BIOXYTRAN, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $504.76K.
- BIOXYTRAN, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$20.93K.
- BIOXYTRAN, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$269.31K, a 220.75% decline from fiscal 2022.
- BIOXYTRAN, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $223.04K, a 627.24% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$332.53K 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$46.87K 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $504.76K 10-K · filed 2026-04-15 | |||
| 2025-09-30 | $9.35K 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | -$2.01K 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$806.00 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$20.93K 10-K · filed 2026-04-15 | |||
| 2024-09-30 | $8.59K 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | -$12.56K 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | -$16.06K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$269.31K 10-K · filed 2025-04-03 | |||
| 2023-09-30 | -$215.13K 10-Q · filed 2024-10-29 | |||
| 2023-06-30 | -$250.22K 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$141.60K 10-Q · filed 2024-04-19 | |||
| 2022-12-31 | $223.04K 10-K/A · filed 2025-01-13 | |||
| 2022-09-30 | $301.83K 10-Q · filed 2023-11-03 | |||
| 2022-06-30 | $428.32K 10-Q · filed 2023-07-31 | |||
| 2022-03-31 | $667.23K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $30.67K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $202.31K 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $346.36K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $49.95K 10-Q · filed 2022-05-23 | |||
| 2020-12-31 | -$127.94K 10-K · filed 2022-04-11 | |||
| 2020-09-30 | -$169.00K 10-Q · filed 2021-11-17 | |||
| 2020-06-30 | -$165.38K 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | -$125.74K 10-Q · filed 2021-05-17 |